Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Operating Income: 2009-2024

Historic Operating Income for Heron Therapeutics (HRTX) over the last 16 years, with Dec 2024 value amounting to -$11.5 million.

  • Heron Therapeutics' Operating Income rose 8.19% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 106.16%. This contributed to the annual value of -$11.5 million for FY2024, which is 89.58% up from last year.
  • According to the latest figures from FY2024, Heron Therapeutics' Operating Income is -$11.5 million, which was up 89.58% from -$110.6 million recorded in FY2023.
  • Heron Therapeutics' Operating Income's 5-year high stood at -$11.5 million during FY2024, with a 5-year trough of -$228.2 million in FY2020.
  • Over the past 3 years, Heron Therapeutics' median Operating Income value was -$110.6 million (recorded in 2023), while the average stood at -$98.9 million.
  • In the last 5 years, Heron Therapeutics' Operating Income fell by 8.29% in 2020 and then surged by 89.58% in 2024.
  • Over the past 5 years, Heron Therapeutics' Operating Income (Yearly) stood at -$228.2 million in 2020, then increased by 4.53% to -$217.8 million in 2021, then rose by 19.82% to -$174.7 million in 2022, then spiked by 36.67% to -$110.6 million in 2023, then spiked by 89.58% to -$11.5 million in 2024.